• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新干预措施的价值评估应包括健康公平影响。

Assessments of the Value of New Interventions Should Include Health Equity Impact.

机构信息

Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California, San Francisco, 490 Illinois Street, Rm 32M, San Francisco, CA, 94158, USA.

Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA, USA.

出版信息

Pharmacoeconomics. 2022 May;40(5):489-495. doi: 10.1007/s40273-022-01131-z. Epub 2022 Mar 3.

DOI:10.1007/s40273-022-01131-z
PMID:35237944
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8890816/
Abstract

A formal evaluation of the health equity impact of a new intervention is hardly ever performed as part of a health technology assessment to understand its value. This should change, in our view. An evidence-based quantitative assessment of the health equity impact can help decision makers develop coverage policies, programme designs, and quality initiatives focused on optimizing both total health and health equity given the treatment options available. We outline the conceptual basis of how a new intervention can impact health equity and adopt distributional cost-effectiveness analysis based on decision-analytic models to assess this quantitatively, using a newly US FDA-approved drug for Alzheimer's disease (aducanumab) as an example. We argue that gaps in the evidence base for the new intervention, for example, due to limited clinical research participation among racial and ethnic minority groups, do not preclude such an evaluation. Understanding these uncertainties has implications for fair pricing, decision making, and future research. If we are serious about population-level decision making that not only is focused on improving total health but also aims to improve health equity, we should consider routinely assessing the health equity impact of new interventions.

摘要

通常情况下,在进行健康技术评估以了解其价值时,很少会对新干预措施的公平性影响进行正式评估。我们认为,这种情况应该改变。基于证据的公平性影响定量评估可以帮助决策者制定覆盖政策、规划设计和质量倡议,以便在现有治疗方案的基础上,优化整体健康和公平性。我们概述了新干预措施如何影响健康公平的概念基础,并采用基于决策分析模型的分布成本效益分析来对此进行定量评估,以最近获得美国 FDA 批准用于治疗阿尔茨海默病的药物(aducanumab)为例。我们认为,新干预措施的证据基础存在差距,例如,由于少数族裔在临床研究中的参与度有限,并不排除这种评估。了解这些不确定性对公平定价、决策和未来研究都具有重要意义。如果我们认真对待以提高整体健康为目标、同时也旨在改善公平性的人群决策,我们应该考虑常规评估新干预措施的公平性影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b92/9095519/41abe335ec0d/40273_2022_1131_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b92/9095519/41abe335ec0d/40273_2022_1131_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b92/9095519/41abe335ec0d/40273_2022_1131_Fig1_HTML.jpg

相似文献

1
Assessments of the Value of New Interventions Should Include Health Equity Impact.新干预措施的价值评估应包括健康公平影响。
Pharmacoeconomics. 2022 May;40(5):489-495. doi: 10.1007/s40273-022-01131-z. Epub 2022 Mar 3.
2
Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.基于组织学的癌症药物建模方法,为 NICE 评估提供信息:系统评价和决策框架。
Health Technol Assess. 2021 Dec;25(76):1-228. doi: 10.3310/hta25760.
3
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges.卫生技术的分布成本效益分析:数据要求与挑战
Value Health. 2023 Jan;26(1):60-63. doi: 10.1016/j.jval.2022.06.011. Epub 2022 Aug 6.
5
Using Cost-Effectiveness Analysis to Address Health Equity Concerns.运用成本效益分析解决健康公平问题。
Value Health. 2017 Feb;20(2):206-212. doi: 10.1016/j.jval.2016.11.027.
6
Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.健康技术的综合分布成本效益分析。
Value Health. 2019 May;22(5):518-526. doi: 10.1016/j.jval.2019.03.006.
7
Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review.卫生干预措施成本效果分析中的公平性效应评估:系统综述。
Value Health. 2021 Jan;24(1):136-143. doi: 10.1016/j.jval.2020.10.010. Epub 2020 Dec 3.
8
How Economic Decision Modeling Can Facilitate Health Equity.经济决策建模如何促进健康公平。
AMA J Ethics. 2021 Aug 1;23(8):E624-630. doi: 10.1001/amajethics.2021.624.
9
Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.为 NICE 何时应仅在适当设计的证据开发计划背景下推荐使用卫生技术制定决策框架提供信息。
Health Technol Assess. 2012;16(46):1-323. doi: 10.3310/hta16460.
10
Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.非小细胞肺癌治疗的分布成本效益分析:综合分析及其关键驱动因素的说明。
Pharmacoeconomics. 2023 Aug;41(8):1011-1025. doi: 10.1007/s40273-023-01281-8. Epub 2023 Jun 9.

引用本文的文献

1
Distributional Cost-Effectiveness Analysis in Genomic Medicine: Considerations for Addressing Health Equity.基因组医学中的分布成本效益分析:解决健康公平问题的考量因素
Value Health. 2025 May 6. doi: 10.1016/j.jval.2025.04.2162.
2
A Research Framework to Improve Health Disparity Evidence Gaps in Value Assessments.一个改善价值评估中健康差异证据差距的研究框架。
Pharmacoeconomics. 2024 Mar;42(3):253-259. doi: 10.1007/s40273-023-01340-0. Epub 2023 Dec 12.
3
Estimating the prevalence of diagnosed Alzheimer disease in England across deprivation groups using electronic health records: a clinical practice research datalink study.

本文引用的文献

1
Estimating Subgroup Effects in Generalizability and Transportability Analyses.在可推广性和可转移性分析中估计亚组效应。
Am J Epidemiol. 2024 Jan 8;193(1):149-158. doi: 10.1093/aje/kwac036.
2
Why the Gap in Evaluating the Social Constructs and the Value of Medicines?为什么在评估药品的社会构建和价值方面存在差距?
Pharmacoeconomics. 2021 Dec;39(12):1365-1372. doi: 10.1007/s40273-021-01075-w. Epub 2021 Aug 30.
3
Measuring Cognitive Health in Ethnically Diverse Older Adults.测量不同族裔老年人群的认知健康。
利用电子健康记录估算英格兰各贫困群体中被诊断为老年痴呆症的流行率:一项临床实践研究数据链接研究。
BMJ Open. 2023 Oct 24;13(10):e075800. doi: 10.1136/bmjopen-2023-075800.
4
The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis.液体活检对指导晚期非小细胞肺癌一线治疗的健康不平等影响:一种分布成本效益分析。
Value Health. 2023 Dec;26(12):1697-1710. doi: 10.1016/j.jval.2023.08.010. Epub 2023 Sep 22.
5
Evidence Clearinghouses as Tools to Advance Health Equity: What We Know from a Systematic Scan.循证知识库作为促进健康公平的工具:系统扫描的结果。
Prev Sci. 2023 May;24(4):613-624. doi: 10.1007/s11121-023-01511-7. Epub 2023 Mar 1.
J Gerontol B Psychol Sci Soc Sci. 2022 Feb 3;77(2):261-271. doi: 10.1093/geronb/gbab062.
4
Diversity and Disparities in Dementia Diagnosis and Care: A Challenge for All of Us.痴呆症诊断与护理中的多样性和差异:对我们所有人的挑战。
JAMA Neurol. 2021 Jun 1;78(6):650-652. doi: 10.1001/jamaneurol.2021.0285.
5
A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States.美国成本效益分析的健康机会成本阈值。
Ann Intern Med. 2021 Jan;174(1):25-32. doi: 10.7326/M20-1392. Epub 2020 Nov 3.
6
Location Matters: Geographic Disparities and Impact of Coronavirus Disease 2019.地点很重要:2019 年冠状病毒病的地理差异和影响。
J Infect Dis. 2020 Nov 13;222(12):1951-1954. doi: 10.1093/infdis/jiaa583.
7
The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States.美国新冠疫情对少数族裔的不成比例影响。
Clin Infect Dis. 2021 Feb 16;72(4):703-706. doi: 10.1093/cid/ciaa815.
8
Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling framework.评估阿尔茨海默病早期干预的成本效益:一个开源建模框架。
Alzheimers Dement. 2019 Oct;15(10):1309-1321. doi: 10.1016/j.jalz.2019.05.004. Epub 2019 Aug 8.
9
Extending inferences from a randomized trial to a target population.将随机试验的推论扩展至目标人群。
Eur J Epidemiol. 2019 Aug;34(8):719-722. doi: 10.1007/s10654-019-00533-2. Epub 2019 Jun 19.
10
The National Institute on Minority Health and Health Disparities Research Framework.国家少数民族健康与健康差异研究所研究框架。
Am J Public Health. 2019 Jan;109(S1):S16-S20. doi: 10.2105/AJPH.2018.304883.